Official Title

Project Limb Rescue: A pilot study evaluating the feasibility of transcutaneous sensors for the detection of cancer-related lymphedema.

Purpose

The goal of the study is to test the success of using two types of sensors at rest after a bike exercise on volunteers with and without lymphedema, to look for differences in their readings. This part of the study will be testing persons who do not have lymphedema.

 

Could this study be right for you?

• No history of cancer related to lymphedema, cancer in your arm, or the lymph nodes in the arm
• Able to complete a brief biking exercise for about seven minutes
• No metal implants
• Willingness to take off shoes and any metal jewelry
• Not currently pregnant
• Not currently incarcerated
• Your participation will involve completing an online or over the phone screening.
• This visit will take approximately 2.5 hours.

Age Range

18 - 90 years

Official Title

Decay of HIV-1 Reservoirs in Participants on Long-Term Antiretroviral Therapy: The ACTG HIV Reservoirs Cohort (AHRC) Study

Purpose

The purpose of this study is to examine longitudinal changes in HIV-1 reservoirs among participants with HIV-1 who are either currently receiving antiretroviral therapy (ART) or who received ART previously. Participants will undergo blood and hair sample collections for immunologic, virologic, and pharmacologic evaluations to study HIV-1 reservoirs in the body.

Could this study be right for you?

This study is currently only enrolling in Group 6 which includes participants who acquired HIV while taking long-acting cabotegravir (CAB).

Age Range

18 years and up

Official Title

A Double-Blind, Randomized, Placebo-Controlled Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined with ART Initiation during Acute HIV Infection to Induce HIV Remission

Purpose

The purpose of this study is to evaluate the safety and efficacy of combination bNAbs in addition to ART initiated during acute HIV infection and to evaluate the impact on HIV viral reservoirs.

Could this study be right for you?

• Newly diagnosed HIV+ individuals who have not yet started antiretroviral therapy (ART)
• Willingness to start ART at enrollment
• Ability and willingness to participate in scheduled study visits and analytic treatment interruption (ATI)
• Weight <115kg

Age Range

18 - 70 years

Official Title

A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Mpox Disease

Purpose

This study will evaluate the safety and efficacy of tecovirimat for the treatment of human monkeypox virus (HMPXV) disease.

Could this study be right for you?

• Lab-confirmed OR suspected HMPXV infection
• At least one active skin lesion, mouth lesion, or proctitis with or without visible ulcers
• HMPXV illness of <14 days duration prior to study entry

Age Range

18 years and up

Official Title

Safety, Tolerability and Immunogenicity of Recombinant HIV Envelope Protein VRC-HIVRGP096-00-VP (Trimer 4571) vaccine, in HIV-1 Infected Adults on suppressive ART

Purpose

The goal of this research study is to see if an investigational vaccine called Trimer 4571 is safe and well tolerated. Additionally, researchers will see if it will help the immune system produce broadly neutralizing antibodies (bNAbs) against HIV. bNAbs are a type of antibody that can recognize and block many types of HIV from entering healthy cells. Trimer 4571 is a vaccine designed to stimulate the development of bnAbs against HIV.

Could this study be right for you?

• On ART for at least 24 months
• HIV RNA <50 for at least 24 months
• CD4 count ≥200
• Known to have started ART during acute HIV infection
• BMI <40kg/m2

Age Range

18 years and up

Official Title

A Phase I/IIa Randomized, Placebo-Controlled Trial of Conserved-Mosaic T-cell Vaccine in a Regimen with Vesatolimod and Broadly Neutralizing Antibodies in Adults Initiated on Suppressive Antiretroviral Therapy during Acute HIV-1

Purpose

This study will evaluate the safety and efficacy of these treatments in individuals with HIV-1 who started suppressive antiretroviral therapy (ART) during acute HIV-1 infection. The study consists of four steps including an analytical treatment interruption (ATI).

Could this study be right for you?

• Individuals with HIV who started treatment during acute HIV infection
• No known ART interruption >14 consecutive days since ART initiation
• Willingness to participate in analytic treatment interruption
• CD4 count ≥500 within 60 days to study entry
• HIV RNA <50 since initial viral suppression on ART and for at least 1 year prior to study entry

Age Range

18 years and up

Official Title

A Phase I Clinical Trial of the Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

Purpose

This study will evaluate the safety, tolerability, and efficacy of N-803 with or without bNAbs, to induce HIV-1 control during an analytic treatment interruption (ATI).

Could this study be right for you?

• HIV RNA <50 for at least 96 weeks
• On a stable ART regimen for at least 96 weeks
• CD4 count above 500
• No known history of CD4 count below 200
• Willingness to participate in analytic treatment interruption (ATI)

Age Range

18 - 70 years

Official Title

State of Ohio Adversity and Resilience Study (SOAR)- Deep Phenotyping

Purpose

The purpose of this study is to develop effective mental health and preventing suicide and substance use disorder, we must better understand risks, which lead to mental illness, and resilience, which allows us to grow even in presence of adversity. This study is looking at how people live and how they deal with distress, depression or drugs and alcohol in Ohio. Family members living in Ohio are asked to participate.

Could this study be right for you?

Eligibility:

Inclusion criteria:

• Adults, age 18-72, and adolescents, age 12-17.

Exclusion criteria:

• Inability to functionally communicate in English.
• Unwilling/unable to sign informed consent or assent document or obtain parental authorization from a parent or legal guardian (subjects <18 years old).
• Inability to understand/follow instructions for study procedures.
• Participants without at least 1 other family member who is willing to participate
  • The definition of family member is subjective to the participant and may not be a blood relative.

Age Range

12 - 72 years

Official Title

Assessing the Impact of an FDA Ban on Menthol Cigarettes on Tobacco-Related Health Disparities in African American Smokers

Purpose

The main reason this study is being done is to assess the impact of the FDA’s (and Columbus) menthol ban on African American (AA) communities. This information will provide the Food and Drug Administration (FDA) with needed information on the impact of a menthol ban on the population most affected by such a policy. The study will focus on collecting survey data on AA menthol smokers’ perception of a menthol ban, their awareness/accessibility to quitting support, and their willingness to enroll in a future study.

Could this study be right for you?

All participants must be self-identified AAs and then sorted into the following categories:

• A Current Menthol smoker is defined as someone who regularly smokes menthol cigarette smokers, at least 5 cigs/day for > 1 year.
• A Former menthol smoker is defined as someone who quit menthol cigarette smoking for >6 months, who previously smoked >5 cigs/day for >1 year.
• Never-smoker is defined as someone who smoked < 100 cigs in their lifetime (CDC definition) and none for >1 year.

Additional eligibility criteria include:

(1) between 21 and 50 years old; (2) access to a smartphone or email, and (3) reading and speaking English.

Age Range

21 - 50 years

Official Title

Ohio Mood Disorder Registry and Repository

Purpose

Mood disorders like Major Depressive Disorder and Bipolar Disorder can be chronic, recurrent illnesses. Our treatments to date can help many people but are often trial and error, and continuity and access to care form major barriers. Our purpose is to create a research registry and repository of individuals with mood disorders who are willing to provide clinical data yearly, and who are willing to be contacted to participate in current and future studies of mood disorders.

Could this study be right for you?

Inclusion Criteria

• 8-70 years of age.
• Fluency or advanced conversational English abilities, by self-report.
• Eligible individuals will have a history of two or more mood disorder episodes (depression events of at least 2 weeks meeting 5 of the criteria for major depressive disorder).

Exclusion Criteria

• Head injury with loss of consciousness of five minutes or greater.
• Hospitalization for drug-related concerns.
• Evidence of intellectual disability.
• Diagnosis of a developmental condition like autism spectrum disorder.
• Evidence of psychosis outside of a mood episode (e.g., schizophrenia).
• Hospitalization or infusion for eating condition.

Age Range

8 - 70 years

Purpose

This study aims at preserving residual hearing and assessing outcomes in cochlear implant patients.

Could this study be right for you?

· Sensorineural hearing loss in both ears acquired after birth

· Better hearing in the low frequencies in the ear to be implanted

· Severe to profound hearing loss in the mid-to-high frequencies in the ear to be implanted

· English-speaking

Inclusion Criteria varies, please contact Study Coordinator. 

Age Range

18 - 79 years

Official Title

A Single-Stage, Adaptive, Open-Label Dose Escalation Safety Study of Adeno-Associated Virus Encoding Human Aromatic L-Amino Acid Decarboxylase (AAV2-hAADC) Administered by MR- guided Infusion into the Midbrain in Pediatric Patients with AADC Deficiency

Purpose

The overall objective of this study is to determine the safety and efficacy of AAV2-hAADC delivered to the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA) in children with aromatic L-amino acid decarboxylase (AADC) deficiency, and to see if there is a demonstration of effective restoration of AADC function by assays of CSF neurotransmitter metabolites and F-DOPA PET imaging, as allowed by subject’s ability to travel to undergo follow-up visits.

Could this study be right for you?

Inclusion Criteria

• Diagnosis of AADC deficiency from genetic test and CSF/blood enzyme test
• Failed to derive adequate benefit from standard medical therapy as judged by presence of residual oculugyric crises and developmental delay.
• Documented history of motor developmental delay, with inability to walk independently without support by age 18 months.
• Both parents (or legal guardians) must give their consent for their child’s participation in the study parents unless (i.) one parent is deceased, unknown or incompetent; (ii.) one parent is not reasonably available; or (iii.) one parent has responsibility for the care and custody of the child.

Inclusion Criteria varies, please contact Study Coordinator for more information.

Exclusion Criteria

• Presence of other significant medical or neurological conditions that would create an unacceptable operative or anesthetic risk.
• Previous stereotactic neurosurgery.
• Coagulopathy, or need for ongoing anticoagulant therapy.
• Receipt of any investigational agent within 60 days prior to Baseline and during study participation.

Exclusion Criteria varies, please contact Study Coordinator for more information. 

Age Range

2 years and up